Are patients with chronic obstructive pulmonary disease at a greater risk for the development of autoimmune thyroiditis as an adverse event of immunotherapy in non-small cell lung cancer treatment?
Our study showed that patients dealing with COPD have a 3.9 times greater risk of developing autoimmune thyroiditis as an adverse event during Pembrolizumab treatment compared with patients without COPD.
Authors
- Aleksandar Jandrić
- Tatjana Adžić‐Vukičević (ORCID: https://orcid.org/0000-0001-7868-6805)
- Ana Blanka-Protić
- Andrej Zecevic
Institutions
- University of Belgrade (RS)
- Institute for Pulmonary Diseases of Vojvodina (RS)
Publication Details
- Journal
- Pathology & Oncology Research
- Published
- 2025-03-14
- DOI
- https://doi.org/10.3389/pore.2025.1612022
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00